PTC Therapeutics Soars 0.51% on Institutional Buying, Price Target Hike

On April 8, 2025, PTC Therapeutics saw a 0.51% rise in pre-market trading.

PTC Therapeutics reported a Q4 loss and missed revenue estimates, with earnings and revenue surprises of 75% and 3.96% respectively. This financial performance may have influenced investor sentiment and contributed to the stock's recent movements.

JPMorgan Chase & Co. raised their price target on PTC Therapeutics from $72.00 to $78.00 and assigned an "overweight" rating, indicating a positive outlook on the company's future prospects. This upgrade could have bolstered investor confidence and driven the stock's pre-market gains.

Headlands Technologies LLC significantly increased its stake in PTC Therapeutics by 843.6% in the fourth quarter, demonstrating strong institutional support for the company. This substantial investment may have contributed to the stock's upward momentum.

American Century Companies Inc. also boosted its holdings in PTC Therapeutics by 66.8% during the same period, further highlighting the growing institutional interest in the company. This increased ownership could have played a role in the stock's recent performance.

PTC Therapeutics' gene therapy for AADC deficiency has been approved in Hong Kong, expanding the company's global reach and potentially opening up new revenue streams. This regulatory milestone could have positively impacted investor sentiment and contributed to the stock's pre-market rise.